




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07F 9/6584, 9/06		A1	(11) International Publication Number: WO 97/22614
			(43) International Publication Date: 26 June 1997 (26.06.97)
(21) International Application Number: PCT/GB96/03157 (22) International Filing Date: 19 December 1996 (19.12.96) (30) Priority Data: 9525891.9 19 December 1995 (19.12.95) GB 9602519.2 8 February 1996 (08.02.96) GB (71) Applicant (for all designated States except US): CHIRO-SCIENCE LIMITED [GB/GB]; Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BRENNAN, Joseph, John [GB/GB]; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). ARMSTRONG, William, Paul [GB/GB]; 69 Gilnahirk Road, Cherryvalley, Belfast, County Antrim BT5 7DE (GB). (74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: IFOSFAMIDE, ANALOGUES THEREOF AND THEIR PREPARATION

(57) Abstract

A compound of formula (I) wherein R¹ and R² are each (CH₂)_mX, R³ is H, each X is Cl or Br and m is 2 or 3, in combination with less than 0.5 % w/w of the corresponding compound wherein R¹ is (CH₂)_mH. Such compounds can be prepared by (i) the reaction of a Bronsted acid or a Lewis acid with NaBH₄ in an organic solvent, and (ii) adding the resultant solution to a solution of a corresponding compound wherein one of R¹ and R² is CO(CH₂)_nX and the other is CO(CH₂)_nX or (CH₂)_mX, wherein n = m-1. Such compounds can also be prepared, in optically-enriched form, starting from an optically-enriched trihaloiminophosphorane of the formula R*N = Phal₃ wherein NR* is a chiral moiety derivable from a chiral amine or chiral sulphonamide of the formula R*NH₂, which can be cyclisable with HO(CH₂)₃NHR.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

IFOSFAMIDE ANALOGUES THEREOF AND THEIR PREPARATION


Field of the invention

This invention relates to processes for the preparation of ifosfamide and analogues thereof, and to the purified compounds themselves.

5 Background of the Invention

Compounds of formula (I)

10



15 wherein two of R¹, R² and R³ are chloroalkyl groups, are potent anti-cancer drugs. Ifosfamide, i.e. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,2,3-oxazaphosphorinane 2-oxide (I: R¹=R²=CH₂CH₂Cl, R³=H) has been found to elicit therapeutic response in human breast, ovarian and lung cancer. WO-A-9600075 and WO-A-9600076 disclose additional therapeutic benefit by the use of non-racemic ifosfamide.

20 Cyclophosphamide (I: R¹=H, R²=R³=CH₂CH₂Cl) has similar effects.

Stec *et al*, Chem. Abs. (1984) 100 no. 5, abstract 034702 (see also PL-A-0119971), disclose the synthesis of ifosfamide by the reduction of phosphoramidate amide functions in compounds of formula I, wherein R¹ is COCH₂Cl, R² is CH₂CH₂Cl, and R³ is H, using diborane as a solution in THF (tetrahydrofuran). EP-
25 A-0295576 discloses using the same starting material, but with borane generated *in situ* in the presence of substrate, using sodium borohydride and boron trifluoride etherate. WO-A-9624600 (published after the priority dates of this Application) discloses a synthesis utilising borane generated *in situ*, sodium borohydride and conc. sulphuric acid.

30 The diborane process is reportedly low-yielding and inconsistent. From a process scale-up perspective, it is uneconomical.

Panckiewicz *et al*, JACS (1979) 101:7712, disclose a synthesis of optically-enriched ifosfamide and similar agents. This process has the problem that the chiral auxiliary, used in a stoichiometric amount, is necessarily destroyed in the process. This is undesirable, from a cost perspective.

5 Summary of the Invention

The present invention is based on our surprising discovery that the *in situ* processes generate a dechloro impurity (I: $R^1=CH_2CH_3$), at a level of 0.5-5.0%. This impurity can be removed, but 2-3 crystallisations are required to give ifosfamide in greater than 99.9% purity. A further discovery is that the level of
10 dechloro impurity is a consequence of the length of exposure of the phosphoramidate and/or the product to sodium borohydride. According to this invention, ifosfamide and its analogues can be prepared in a form containing less than 0.5%, preferably less than 0.2%, and most preferably less than 0.1%, by weight of the dechloro impurity.

15 According to a first process aspect of the present invention, it has been found that pregeneration of borane using sodium borohydride and an acidic reagent, prior to contact with the substrate, is a more efficient system for the conversion of compounds of formula I, wherein R^1 is $COCH_2Cl$, and also of compounds where R^2 is $COCH_2Cl$. The acidic reagent may either be a Lewis acid (e.g. $BF_3 \cdot OEt_2$) or a
20 Bronsted acid (e.g. CF_3COOH or H_2SO_4).

A second process aspect of the present invention is based on the discovery that novel trichloroimino-phosporanes, derived from chiral amines, undergo cyclisation reactions with 3-amino-1-propanol and *N*-alkylated derivatives thereof, with useful levels of diastereoselectivity. The resultant products can then be
25 converted to, say, optically-enriched ifosfamide, with recovery of the chiral amine. This and other discoveries can be readily utilised in preparing pure product, i.e. ifosfamide or an analogue thereof. Such analogues are defined in the claims (where substituents usually, unless otherwise defined, have up to 6, 8, 10 or 12 C atoms).

As a consequence of this invention, it is now possible to conduct a
30 reproducible reduction procedure which gives non-racemic ifosfamide to a British Pharmacopoeia standard, thus allowing its formulation as a safe pharmaceutical drug.

In particular, either enantiomer of ifosfamide or an analogue thereof can be produced, e.g. in at least 80 or 90% ee, substantially free of the dechloro impurity. The dechloro impurity can be detected using either gas chromatography or HPLC with the UV detector set at 195 nm for example.

5 Description of the Invention

 In the first novel process, the system generates borane in ethereal solvent at temperatures less than 10°C. This reducing system is then preferably used by being syphoned into an ethereal solution of the phosphoramidate amide to be reduced. This simple procedure, involving a new mode of addition, represents significant
10 advantages over the prior art because the dechloro impurity is reduced sufficiently that multiple crystallisations are not required.

 The novel optically-enriched trihaloiminophosphoranes used in the second process of the invention may be prepared by the Kirsanov reaction; see, for example, Kirsanov, Zh. Obshch. Khim. (1952) 22:269, and Johnston, in Ylides and Imines
15 of Phosphorus, Ch. 13, pub. Wiley, New York (1993). Thus, the reaction of phosphorus pentachloride and single enantiomer R*-NH₂, where R*-NH₂ is a chiral amine (e.g. 1-phenethylamine) or a chiral sulphonamide (e.g. 10-camphorsulphonamide), gives optically-enriched trichloroiminophosphoranes. These compounds can be considered as chiral phosphorus oxychloride equivalents, and are useful
20 intermediates for the preparation of the cytotoxic oxazaphosphorinanes such as ifosfamide and cyclophosphamide.

 These reactions are depicted in Scheme 1; this shows by way of example the production of optically-enriched ifosfamide (* indicates the chiral centre on P) and recovered auxiliary. The reactions shown in Scheme 1 are equally applicable to the
25 preparation of the analogues of claims 9, 10 and 11; any modification that may be necessary will be readily apparent to one of ordinary skill in the art. The heterocyclic N atom may be unsubstituted or substituted, e.g. by a protecting group. Suitable protecting groups are well known to those of ordinary skill in the art, and can be introduced and removed by known procedures.

30 More specifically, reaction of the trichloroimino-phosphorane 1 with *N*-(2-chloroethyl)-3-amino-1-propanol gives the key intermediate 2 for the synthesis of ifosfamide. Similarly, reaction of 1 with 3-amino-1-propanol gives the key

intermediate in the synthesis of cyclophosphamide. Such conversions are synthetically useful since cyclisation products such as 2 are formed with appreciable levels of diastereoselectivity. Subsequent reaction of intermediate 2 with 2-chloroethylamine, followed by hydrolysis of the auxiliary, gives optically-enriched ifosfamide.

A preferred embodiment of the present invention is the use of carbonyl-containing auxiliaries such as 10-camphorsulphonamide, since at the end of the synthetic sequence these can be liberated and recovered by means of an intramolecular aza-Wittig reaction, followed by hydrolysis. More generally, the hydrolysis reaction may involve reacting the oxazaphosphorinane with a reagent that converts the $P=NR^*$ group to $P=O$, the essential reagent being H_2O or one that releases NR^* as a product that is then hydrolysed to H_2NR^* .

Where base is required in a process of the invention, any suitable base may be readily chosen by one of ordinary skill in the art. Examples are trialkylamines, N,N-disubstituted anilines and heterocyclic compounds which are basic, for example pyridine or imidazole.

Where a solvent is required in a process of the invention, any suitable solvent may be chosen by one of ordinary skill in the art. Examples are alkanes, aromatic hydrocarbons (e.g. toluene, xylene, etc), chlorinated solvents (such as dichloromethan), ethers and esters.

The following Examples illustrate the invention.

Example 1

To a suspension of $NaBH_4$ (0.83 g, 0.02 moles) in THF (30 ml) was added conc. H_2SO_4 (0.61 ml, 0.01 moles) dropwise at $5^\circ C$ under N_2 atmosphere. The reducing medium was syphoned under positive N_2 pressure into a stirred solution of 3(R)-chloroacetyl-2-(2-chloroethylamino)-1,3,2-oxazaphosphorinane 2-oxide (5.0 g, 0.018 moles) in THF (30 ml). After complete addition, the reaction was stirred at $5-10^\circ C$ for 1 hr, then allowed to warm to $20^\circ C$ over 2 hr. The reaction was quenched into water (35 ml) with vigorous stirring at $0^\circ C$. The resulting clear solution was stirred for 2 hr at $0-10^\circ C$. The THF was removed and the aqueous layer extracted with chloroform. The organics were dried, filtered and reduced to

yield crude product (3.70 g, 78%). The crude (*R*)-ifosfamide was crystallised from methyl *tert*-butyl ether/heptane, with 90% recovery.

Example 2

The procedure of Example 1 was repeated with $\text{BF}_3 \cdot \text{OEt}_2$ (2.63 ml, 0.02 moles) instead of conc. H_2SO_4 . The crude product was isolated as a white solid (4.3 g, 91%) and crystallised from *tert*-butyl acetate/hexane, with 77% recovery.

Example 3 (*S*)-(α -Methylbenzyl)iminotrichlorophosphorane

(*S*)- α -Methylbenzylamine (2.42 g, 0.02 mol) was added over 5 min to a mechanically-stirred slurry of phosphorus pentachloride (4.16 g, 0.02 mol) in carbon tetrachloride (25 ml) over nitrogen. Heat was applied to bring the reaction to reflux, and the initially-formed precipitate began to go into solution. Reflux was maintained for 4 h, to remove all the hydrogen chloride, leaving a yellow-coloured solution. The carbon tetrachloride was removed under reduced pressure, to leave a pale yellow oil which comprised fairly pure product (5.1 g, 95%). This crude material was distilled under reduced pressure, to give the product as a clear oil (b.p. 70-72°C at 6×10^{-3} mm Hg).

Example 4 (1*S*)-(10-Camphorsulphonyl)iminotrichlorophosphorane

A mixture of (1*S*)-10-camphorsulfonamide (2.0 g, 8.66 mmol) and phosphorus pentachloride (1.8 g, 8.66 mmol) was refluxed in carbon tetrachloride (25 ml) for 3 h. The resulting clear solution was evaporated at reduced pressure, to leave an oil which rapidly solidified to a white solid (3.2 g, 90%). This material was used without further purification.


Example 5 3-Benzyl-2-[*N*-(1*S*)-10-camphorsulfonylimino]-2-chlorotetrahydro-2H-1,3,2-oxazophosphorinane (R_pS_p -diastereomeric mixture)

To a mechanically-stirred solution of the product of Example 4 (10.0 g, 27.2 mmol) in dry toluene (150 ml) at -10°C, under nitrogen, was added a mixture of *N*-benzyl-3-aminopropanol (4.5 g, 27.2 mmol) and triethylamine over 30 min. The reaction mixture was stirred vigorously and allowed to warm to room temperature over 4 h. It was filtered, and the toluene was then removed under reduced pressure at 50°C, to leave a pale yellow gum (13.2 g). ^{31}P nmr analysis shows two diastereomer peaks around 8.43 (d.e. 52%). The oil was purified by flash

chromatography on silica gel, using hexane/ethyl acetate, to give pure product as a mixture of diastereomers (d.e. 58%, 10.0 g, 80%).


Example 6 3-Benzyl-2-[*N*-(1*S*)-10-camphorsulfonylimino]-2-(2-chloroethylamino)tetrahydro-2*H*-1,3,2-oxazophosphorinane (*R_pS_p*-diastereomeric mixture)

The product of Example 5 (2.0 g, 4.36 mmol, d.e. 58%) and 2-chloroethylamine hydrochloride (0.58 g, 5 mmol) were stirred in dry chloroform (60 ml) under nitrogen at room temperature. Triethylamine (1.39 ml, 10 mmol) was added over 5 min, and the mixture was then heated under reflux for 2 h. The reaction mixture was washed with water (100 ml) and brine (100 ml), and dried over sodium sulphate, and the solvent was removed *in vacuo* to leave the product (2.01 g, 90%) as a pale yellow oil as a mixture of diastereomers (d.e. = 50%).

Scheme 1

CLAIMS

1. A compound of formula I



wherein R^1 and R^2 are each $(CH_2)_mX$, R^3 is H, each X is Cl or Br and m is 2 or 3, in combination with less than 0.5% w/w of the corresponding compound wherein R^1 is $(CH_2)_mH$.

2. A compound according to claim 1, in admixture with less than 0.2% of said corresponding compound.

3. A compound according to claim 1, in admixture with less than 0.1% of said corresponding compound.

4. A compound according to any preceding claim, wherein m is 2.


5. A compound according to claim 4, which is ifosfamide.

6. A compound according to any preceding claim, in optically-enriched form.

7. A compound according to claim 6, wherein the enantiomeric excess is at least 80% ee.

8. A process for the preparation of a compound according to any of claims 1 to 7, which comprises (i) the reaction of a Bronsted acid or a Lewis acid with $NaBH_4$ in an organic solvent, and (ii) adding the resultant solution to a solution of a corresponding compound wherein one of R^1 and R^2 is $CO(CH_2)_nX$ and the other is $CO(CH_2)_nX$ or $(CH_2)_mX$, wherein $n = m-1$.


9. An optically-enriched trihaloiminophosphorane of the formula



wherein NR^* is a chiral moiety derivable from a chiral amine or chiral sulphonamide of the formula R^*NH_2 .

10. An optically-enriched halooxazaphosphorinane of the formula


5



- 10 wherein R* is as defined in claim 9; and R is H, alkyl, haloalkyl, arylalkyl, acyl or haloacyl, or a protecting group.

11. An optically-enriched oxazaphosphorinane of the formula

15



20

wherein R* is as defined in claim 9; R is as defined in claim 10; and R' and R'' are independently H, haloalkyl, hydroxyalkyl or haloacyl.

12. A compound according to claim 10 or claim 11, wherein R and R' are as defined for R¹ and R² in any of claims 1, 4 and 5, and R'' is H.
- 25 13. Use of a compound according to any of claims 9 to 12, for the preparation of optically-enriched ifosfamide or cyclophosphamide.
14. A process for preparing a trihaloiminophosphorane according to claim 9, which comprises the reaction of a phosphorus pentahalide with R*NH₂ in the presence of base, in an inert solvent.
- 30 15. A process for preparing a halooxazaphosphorinane according to claim 10, which comprises the reaction of HO(CH₂)₃NHR with a trihaloiminophosphorane according to claim 9, in the presence of a base, in an inert solvent.

16. A process for preparing an oxazaphosphorinane according to claim 11, which comprises reaction of a halooxazaphosphorinane according to claim 10 with an amine $\text{HNR}'\text{R}''$ in the presence of base, in an inert solvent.
17. A process for preparing a compound according to claim 6 or claim 7, which
5 comprises the removal and recovery of the chiral auxiliary H_2NR^* from an oxazaphosphorinane according to claim 11 and, if necessary, converting R to $(\text{CH}_2)_m\text{X}$, and $\text{NR}'\text{R}''$ to $\text{NH}-(\text{CH}_2)_m\text{X}$.
18. A process according to claim 17, wherein removal of the chiral auxiliary comprises reaction with water under acidic or basic conditions.
- 10 19. A process according to claim 17, wherein removal of the chiral auxiliary comprises an aza-Wittig reaction.
20. A process according to claim 19, wherein the aza-Wittig reaction is an intramolecular process.
21. A process according to claim 20, which comprises using a carbonyl-
15 containing reagent.

INTERNATIONAL SEARCH REPORT

International Application No

PL./GB 96/03157

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07F9/6584 C07F9/06

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 295 576 A (INSTITUT PRZEMYSŁU FARMACEUTYCZNEGO) 21 December 1988 cited in the application see the whole document ---	1-21
A	GB 1 553 984 A (POLSKA AKADEMIA) 17 October 1979 see the whole document ---	1-21
A	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 101, no. 26, 19 December 1979, pages 7712-7718, XP000609186 PANKIEWICZ K ET AL: "SYNTHESIS AND ABSOLUTE CONFIGURATION ASSIGNMENTS OF ENANTIOMERIC FORMS OF IFOSPHAMIDE, SULFOSPHAMIDE, AND TROFOSPHAMIDE" cited in the application see the whole document ---	1-21
-/--		

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 April 1997

Date of mailing of the international search report

22.04.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Beslier, L

INTERNATIONAL SEARCH REPORT

International Application No

PC/GB 96/03157

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZEITSCHRIFT FUR ANORGANISCHE UND ALLGEMEINE CHEMIE, vol. 406, no. 2/03, 1974, pages 214-220, XP000611244 KLEIN H A ET AL: "UNTERSUCHUNGEN UEBER PHOSPHAZOVERBINDUNGEN AUS ANILINEN MIT PHOSPHORPENTACHLORID INVESTIGATIONS ON PHOSPHAZO COMPOUNDS FROM ANILINES WITH PHOSPHORUS PENTACHLORIDE" see the whole document ---	1-21
P,A	WO 96 24600 A (CHIROSCIENCE LTD.) 15 August 1996 cited in the application see the whole document ---	1-21
P,A	WO 96 00076 A (CHIROSCIENCE LTD.) 4 January 1996 cited in the application see the whole document ---	1-21
P,A	WO 96 00075 A (CHIROSCIENCE LTD.) 4 January 1996 cited in the application see the whole document ---	1-21
P,A	EP 0 692 470 A (DEGUSSA AG) 17 January 1996 see the whole document -----	1-21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC/GB 96/03157

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 295576 A	21-12-88	DE 3881103 A	24-06-93
		DE 3881103 T	23-12-93
		US 4908464 A	13-03-90

GB 1553984 A	17-10-79	CH 623594 A	15-06-81
		DE 2644905 A	14-04-77

WO 9624600 A	15-08-96	AU 4630396 A	27-08-96

WO 9600076 A	04-01-96	AU 2747495 A	19-01-96
		FI 965171 A	20-12-96
		AU 7789394 A	19-01-96

WO 9600075 A	04-01-96	AU 7789394 A	19-01-96
		CA 2170136 A	04-01-96

EP 692470 A	17-01-96	DE 4425070 A	18-01-96
		JP 8169877 A	02-07-96
